N-[(3S,5R)-1-(8-cyanoquinoxalin-5-yl)-5-(trifluoromethyl)piperidin-3-yl]-2-(4-methylpiperazin-1-yl)acetamide
C22H26F3N7O — CID 129241030
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[(3S,5R)-1-(8-cyanoquinoxalin-5-yl)-5-(trifluoromethyl)piperidin-3-yl]-2-(4-methylpiperazin-1-yl)acetamide
N-[(3S,5R)-1-(8-cyanoquinoxalin-5-yl)-5-(trifluoromethyl)piperidin-3-yl]-2-(4-methylpiperazin-1-yl)acetamide (PubChem CID 129241030) has the molecular formula C22H26F3N7O and a molecular weight of 461.49 g/mol. Its IUPAC name is N-[(3S,5R)-1-(8-cyanoquinoxalin-5-yl)-5-(trifluoromethyl)piperidin-3-yl]-2-(4-methylpiperazin-1-yl)acetamide.
Molecular Properties
| Compound Name | N-[(3S,5R)-1-(8-cyanoquinoxalin-5-yl)-5-(trifluoromethyl)piperidin-3-yl]-2-(4-methylpiperazin-1-yl)acetamide |
|---|---|
| PubChem CID | 129241030 |
| Molecular Formula | C22H26F3N7O |
| Molecular Weight | 461.49 g/mol |
| Exact Mass | 461.22 |
| IUPAC Name | N-[(3S,5R)-1-(8-cyanoquinoxalin-5-yl)-5-(trifluoromethyl)piperidin-3-yl]-2-(4-methylpiperazin-1-yl)acetamide |
| SMILES | CN1CCN(CC(=O)N[C@H]2C[C@@H](C(F)(F)F)CN(c3ccc(C#N)c4nccnc34)C2)CC1 |
| InChI | InChI=1S/C22H26F3N7O/c1-30-6-8-31(9-7-30)14-19(33)29-17-10-16(22(23,24)25)12-32(13-17)18-3-2-15(11-26)20-21(18)28-5-4-27-20/h2-5,16-17H,6-10,12-14H2,1H3,(H,29,33)/t16-,17+/m1/s1 |
| InChIKey | WHCRCZKBYNQFDP-SJORKVTESA-N |
| XLogP | 1.62 |
| TPSA | 88.39 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 461.49 |
| LogP ≤ 5 | 1.62 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 129241030 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.